ZA200708839B - Pharmaceutical compositions comprising imatinib and a release retardant - Google Patents

Pharmaceutical compositions comprising imatinib and a release retardant

Info

Publication number: ZA200708839B
Authority: ZA; South Africa
Prior art keywords: imatinib; pharmaceutical compositions; release retardant; retardant; release
Prior art date: 2005-05-10

Application number

ZA200708839A

Other languages

English (en)

Inventor

Vasanthavada Madhav

Lakshman Jay Parthiban

Tong Wei-Qin

Abu T M Serajuddin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-10

Filing date

2007-10-16

Publication date

2008-11-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200708839(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-10-16 Application filed by Novartis Ag filed Critical Novartis Ag

2008-11-26 Publication of ZA200708839B publication Critical patent/ZA200708839B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
- B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
- B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
- B29C48/04—Particle-shaped
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
- B29C48/05—Filamentary, e.g. strands
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
- B29C48/06—Rod-shaped
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/25—Component parts, details or accessories; Auxiliary operations
- B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
- B29C48/395—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
- B29C48/40—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws or at least two parallel non-intermeshing screws, e.g. twin screw extruders
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/25—Component parts, details or accessories; Auxiliary operations
- B29C48/88—Thermal treatment of the stream of extruded material, e.g. cooling
- B29C48/911—Cooling
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
- B29K2001/08—Cellulose derivatives
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/25—Solid
- B29K2105/251—Particles, powder or granules
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0056—Biocompatible, e.g. biopolymers or bioelastomers
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0059—Degradable
- B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mechanical Engineering (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Thermal Sciences (AREA)
Zoology (AREA)
Botany (AREA)
Hematology (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)

ZA200708839A 2005-05-10 2007-10-16 Pharmaceutical compositions comprising imatinib and a release retardant ZA200708839B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US67960705P	2005-05-10	2005-05-10

Publications (1)

Publication Number	Publication Date
ZA200708839B true ZA200708839B (en)	2008-11-26

Family

ID=37027884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200708839A ZA200708839B (en)	2005-05-10	2007-10-16	Pharmaceutical compositions comprising imatinib and a release retardant

Country Status (32)

Country	Link
US (2)	US20080226731A1 (fr)
EP (1)	EP1888040B1 (fr)
JP (1)	JP5054000B2 (fr)
KR (2)	KR20080007249A (fr)
CN (1)	CN101175483B (fr)
AR (1)	AR054114A1 (fr)
AT (1)	ATE477794T1 (fr)
AU (1)	AU2006244359B2 (fr)
BR (1)	BRPI0608605A2 (fr)
CA (1)	CA2606602C (fr)
CY (1)	CY1111389T1 (fr)
DE (1)	DE602006016270D1 (fr)
DK (1)	DK1888040T3 (fr)
ES (1)	ES2350002T3 (fr)
GT (1)	GT200600194A (fr)
HR (1)	HRP20100615T1 (fr)
IL (1)	IL186925A (fr)
JO (1)	JO2647B1 (fr)
MA (1)	MA29463B1 (fr)
MX (1)	MX2007014067A (fr)
MY (1)	MY148074A (fr)
NO (1)	NO20076288L (fr)
NZ (1)	NZ562538A (fr)
PE (1)	PE20061449A1 (fr)
PL (1)	PL1888040T3 (fr)
PT (1)	PT1888040E (fr)
RU (1)	RU2404775C2 (fr)
SA (1)	SA06270134B1 (fr)
TN (1)	TNSN07417A1 (fr)
TW (1)	TWI368523B (fr)
WO (1)	WO2006121941A2 (fr)
ZA (1)	ZA200708839B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1628685E (pt)	2003-04-25	2011-03-16	Gilead Sciences Inc	Análogos de fosfonatos antivirais
BRPI0512690A (pt)	2004-07-27	2007-11-27	Gilead Sciences Inc	análogos de fosfonato de compostos inibidores de hiv
DE502006005084D1 (de) *	2005-08-15	2009-11-26	Siegfried Generics Int Ag	Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
HRP20110250T1 (hr)	2006-09-22	2011-05-31	Novartis Ag	Optimalizacija liječenja philadelphia-pozitivne leukemije s imatinibom inhibitorom abl-tirozin kinaze
EP1920767A1 (fr) *	2006-11-09	2008-05-14	Abbott GmbH & Co. KG	Forme posologique d'Imatinib préparée à l'état fondu.
BRPI0808840A2 (pt) *	2007-03-12	2014-09-02	Reddy S Laborartories Ltd Dr	Mesilato de imatinib
AU2012201613B2 (en) *	2007-06-07	2014-12-04	Novartis Ag	Stabilized amorphous forms of Imatinib mesylate
PT2305263E (pt) *	2007-06-07	2012-10-22	Novartis Ag	Formas amorfas estabilizadas de mesilato de imatinib
EP2191848A4 (fr) *	2007-08-31	2013-05-15	Daiichi Sankyo Co Ltd	Préparation à libération prolongée et procédé de fabrication de celle-ci
WO2009042803A1 (fr)	2007-09-25	2009-04-02	Teva Pharmaceutical Industries Ltd.	Compositions d'imatinib
MX2010008103A (es) *	2008-01-23	2010-08-23	Novartis Ag	Metodo para optimizar el tratamiento de enfermedades proliferativas mediadas por el receptor de cinasa de tirosina kit con imatinib.
WO2009100176A2 (fr) *	2008-02-07	2009-08-13	Abbott Laboratories	Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
JP2011520779A (ja) *	2008-03-21	2011-07-21	エラン・ファルマ・インターナショナル・リミテッド	イマチニブの部位特異的送達のための組成物および使用の方法
PT2307435E (pt) *	2008-07-08	2012-09-19	Gilead Sciences Inc	Sais de compostos inibidores de vih
WO2010065433A1 (fr)	2008-12-01	2010-06-10	Novartis Ag	Méthode d’optimisation du traitement de la leucémie philadelphie positive avec du mésylate d’imatinib
CA2789307A1 (fr) *	2010-03-29	2011-10-06	Hetero Research Foundation	Composition pharmaceutique stable d'imatinib
US20130085145A1 (en) *	2010-06-21	2013-04-04	Suven Life Sciences Limited	Imatinib mesilate pharmaceutical tablet
EP2603288A1 (fr)	2010-08-11	2013-06-19	Synthon BV	Granulat pharmaceutique comprenant de l'imatinib mésylate
WO2012080703A1 (fr)	2010-12-15	2012-06-21	Cipla Limited	Composition pharmaceutique comprenant de l'imatinib
TR201010618A2 (tr) *	2010-12-20	2012-07-23	Bi̇lgi̇ç Mahmut	İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) *	2011-03-09	2012-09-10	Adamed Spółka Z Ograniczoną Odpowiedzialnością	Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) *	2011-06-22	2017-09-05	Natco Pharma Limited	Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2013008253A2 (fr) *	2011-07-11	2013-01-17	Dr. Reddys Laboratories Limited	Formulations d'imatinib
JP6086520B2 (ja) *	2011-08-22	2017-03-01	大原薬品工業株式会社	薬物高含有固形製剤
EA026665B1 (ru)	2011-11-24	2017-05-31	Имунекс Фарма Илак Санайи Ве Тикарет А.С.	Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
KR101428149B1 (ko) *	2011-12-23	2014-08-08	씨제이헬스케어 주식회사	이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
US9757465B2 (en) *	2012-04-11	2017-09-12	Dow Global Technologies Llc	Composition comprising an organic diluent and a cellulose ether
WO2013154981A1 (fr) *	2012-04-11	2013-10-17	Dow Global Technologies Llc	Composition extrudée par fusion comportant un éther de cellulose
BR112014020719B1 (pt) *	2012-04-11	2020-03-03	Dow Global Technologies Llc	Forma de dosagem de liberação constante, método para preparar uma forma de dosagem de liberação constante e uso de um éter de celulose
RU2517216C2 (ru) *	2012-08-22	2014-05-27	Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД")	Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
US9956709B2 (en) *	2013-05-27	2018-05-01	Steerlife India Private Limited	Hot melt fragmentation extruder and process
AU2014288866B2 (en) *	2013-07-09	2017-07-13	Shilpa Medicare Limited	Oral pharmaceutical compositions comprising Imatinib mesylate
WO2015165975A1 (fr) *	2014-04-29	2015-11-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et compositions pour traiter des néoplasies myéloïdes
CN104146973B (zh) *	2014-08-14	2017-09-05	杭州华东医药集团新药研究院有限公司	一种含有甲磺酸伊马替尼组合物及其制备方法
US20160331689A1 (en) *	2015-05-12	2016-11-17	SE Tylose USA, Inc.	Aqueous enteric coating composition
SE539450C2 (en)	2016-02-29	2017-09-26		Imatinib for use in the treatment of stroke
PT3661937T (pt)	2017-08-01	2021-09-24	Gilead Sciences Inc	Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
EA033102B1 (ru) *	2017-08-21	2019-08-30	Общество с ограниченной ответственностью "Фармамед"	Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
MX2022000418A (es) *	2019-07-15	2022-02-10	Intas Pharmaceuticals Ltd	Composicion farmaceutica de imatinib.
AU2021391823A1 (en)	2020-12-03	2023-06-29	Battelle Memorial Institute	Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
IL307454A (en)	2021-04-07	2023-12-01	Battelle Memorial Institute	Technologies for rapid design, construction, testing, learning to identify and use non-viral vectors
WO2025072751A1 (fr)	2023-09-29	2025-04-03	Battelle Memorial Institute	Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025122954A1 (fr)	2023-12-08	2025-06-12	Battelle Memorial Institute	Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4684516A (en) *	1983-08-01	1987-08-04	Alra Laboratories, Inc.	Sustained release tablets and method of making same
US4861598A (en) *	1986-07-18	1989-08-29	Euroceltique, S.A.	Controlled release bases for pharmaceuticals
DE4031881C2 (de) *	1990-10-08	1994-02-24	Sanol Arznei Schwarz Gmbh	Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5948438A (en) *	1995-01-09	1999-09-07	Edward Mendell Co., Inc.	Pharmaceutical formulations having improved disintegration and/or absorptivity
US20010014352A1 (en) *	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
DE10015479A1 (de) *	2000-03-29	2001-10-11	Basf Ag	Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
DE10026699A1 (de) *	2000-05-30	2001-12-06	Basf Ag	Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
EP1364660B1 (fr) *	2001-02-27	2010-12-22	Senju Pharmaceutical Co., Ltd.	Systeme de liberation de medicament de type polymere biodegradable
DE10207586A1 (de)	2002-02-22	2003-09-11	Degussa	Herstellung von N-Methyl-3-hydroxy-3-(2-thienyl)propanamin über neue carbamatgruppenhaltige Thiophenderivate als Zwischenprodukte
WO2003077892A2 (fr) *	2002-03-15	2003-09-25	Novartis Ag	4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide pour le traitement de maladies induites par l'angiotensine ii
GB0209265D0 (en) *	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
WO2003094904A1 (fr) *	2002-05-13	2003-11-20	Beth Israel Deaconess Medical Center	Methodes et compositions de traitement du rejet de greffe
DE102005005446A1 (de) *	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
WO2006040779A2 (fr) *	2004-10-11	2006-04-20	Natco Pharma Limited	Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
WO2006048890A1 (fr) *	2004-11-04	2006-05-11	Sun Pharmaceutical Industries Limited	Forme cristalline d'imatinib mesylate et procede d'elaboration

2006
- 2006-05-04 MY MYPI20062055A patent/MY148074A/en unknown
- 2006-05-08 EP EP06759225A patent/EP1888040B1/fr active Active
- 2006-05-08 KR KR1020077026121A patent/KR20080007249A/ko not_active Ceased
- 2006-05-08 HR HR20100615T patent/HRP20100615T1/hr unknown
- 2006-05-08 PT PT06759225T patent/PT1888040E/pt unknown
- 2006-05-08 SA SA06270134A patent/SA06270134B1/ar unknown
- 2006-05-08 JP JP2008511210A patent/JP5054000B2/ja not_active Expired - Fee Related
- 2006-05-08 AR ARP060101844A patent/AR054114A1/es unknown
- 2006-05-08 CA CA2606602A patent/CA2606602C/fr not_active Expired - Fee Related
- 2006-05-08 DE DE602006016270T patent/DE602006016270D1/de active Active
- 2006-05-08 RU RU2007145507/15A patent/RU2404775C2/ru not_active IP Right Cessation
- 2006-05-08 BR BRPI0608605-5A patent/BRPI0608605A2/pt not_active Application Discontinuation
- 2006-05-08 WO PCT/US2006/017558 patent/WO2006121941A2/fr not_active Ceased
- 2006-05-08 PE PE2006000486A patent/PE20061449A1/es not_active Application Discontinuation
- 2006-05-08 CN CN2006800161312A patent/CN101175483B/zh not_active Expired - Fee Related
- 2006-05-08 KR KR1020107007624A patent/KR101156916B1/ko not_active Expired - Fee Related
- 2006-05-08 US US11/913,774 patent/US20080226731A1/en not_active Abandoned
- 2006-05-08 DK DK06759225.3T patent/DK1888040T3/da active
- 2006-05-08 MX MX2007014067A patent/MX2007014067A/es active IP Right Grant
- 2006-05-08 AT AT06759225T patent/ATE477794T1/de active
- 2006-05-08 NZ NZ562538A patent/NZ562538A/en not_active IP Right Cessation
- 2006-05-08 AU AU2006244359A patent/AU2006244359B2/en not_active Ceased
- 2006-05-08 PL PL06759225T patent/PL1888040T3/pl unknown
- 2006-05-08 ES ES06759225T patent/ES2350002T3/es active Active
- 2006-05-09 JO JO2006128A patent/JO2647B1/en active
- 2006-05-09 GT GT200600194A patent/GT200600194A/es unknown
- 2006-05-09 TW TW095116437A patent/TWI368523B/zh not_active IP Right Cessation
2007
- 2007-10-16 ZA ZA200708839A patent/ZA200708839B/xx unknown
- 2007-10-25 IL IL186925A patent/IL186925A/en not_active IP Right Cessation
- 2007-11-09 TN TNP2007000417A patent/TNSN07417A1/en unknown
- 2007-11-20 MA MA30391A patent/MA29463B1/fr unknown
- 2007-12-06 NO NO20076288A patent/NO20076288L/no unknown
2010
- 2010-11-12 CY CY20101101022T patent/CY1111389T1/el unknown
2014
- 2014-06-10 US US14/300,511 patent/US20140350027A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE602006016270D1 (de)	2010-09-30
PE20061449A1 (es)	2007-01-20
CY1111389T1 (el)	2015-08-05
RU2404775C2 (ru)	2010-11-27
AU2006244359B2 (en)	2010-12-09
US20080226731A1 (en)	2008-09-18
AR054114A1 (es)	2007-06-06
DK1888040T3 (da)	2010-11-15
ATE477794T1 (de)	2010-09-15
EP1888040A2 (fr)	2008-02-20
WO2006121941A2 (fr)	2006-11-16
EP1888040B1 (fr)	2010-08-18
SA06270134B1 (ar)	2009-02-07
WO2006121941A3 (fr)	2007-01-11
TNSN07417A1 (en)	2009-03-17
GT200600194A (es)	2006-12-04
CN101175483B (zh)	2012-06-20
BRPI0608605A2 (pt)	2010-01-19
CA2606602A1 (fr)	2006-11-16
KR20100044286A (ko)	2010-04-29
HRP20100615T1 (hr)	2010-12-31
NZ562538A (en)	2011-03-31
IL186925A (en)	2011-11-30
US20140350027A1 (en)	2014-11-27
JP5054000B2 (ja)	2012-10-24
CN101175483A (zh)	2008-05-07
MX2007014067A (es)	2008-02-07
MA29463B1 (fr)	2008-05-02
NO20076288L (no)	2008-02-05
TW200716205A (en)	2007-05-01
IL186925A0 (en)	2008-02-09
CA2606602C (fr)	2013-08-27
JO2647B1 (en)	2012-06-17
RU2007145507A (ru)	2009-06-20
PT1888040E (pt)	2010-10-28
HK1116067A1 (en)	2008-12-19
MY148074A (en)	2013-02-28
AU2006244359A1 (en)	2006-11-16
TWI368523B (en)	2012-07-21
PL1888040T3 (pl)	2011-02-28
ES2350002T3 (es)	2011-01-14
KR101156916B1 (ko)	2012-06-21
JP2008540531A (ja)	2008-11-20
KR20080007249A (ko)	2008-01-17

Publication	Publication Date	Title
TWI368523B (en)	2012-07-21	Pharmaceutical compositions comprising imatinib and a release retardant
EP1945197A4 (fr)	2010-08-11	Compositions pharmaceutiques stabilisées et à libération retardée qui comprennent un antagoniste de bêta-adrénorécepteur
IL188964A0 (en)	2008-08-07	Sustained drug release composition
EP2056835A4 (fr)	2013-01-30	Compositions pharmaceutiques et leurs utilisations
IL179809A0 (en)	2007-05-15	Pharmaceutical compositions
ZA200705530B (en)	2008-10-29	Sustained release pharmaceutical formulations
GB0409703D0 (en)	2004-06-02	Pharmaceutical compositions
ZA200802947B (en)	2009-12-30	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
GB0408308D0 (en)	2004-05-19	Pharmaceutical compositions
IL188352A0 (en)	2008-04-13	Pharmaceutical compositions
ZA200804103B (en)	2009-10-28	Pharmaceutical compositions
EP1885665A4 (fr)	2012-05-02	Formulations de dithiocarbamates et de phosphite
EP1802346A4 (fr)	2011-07-06	Composition pharmaceutique à libération prolongée
IL192091A0 (en)	2008-12-29	Pharmaceutical compositions
IL186337A0 (en)	2008-01-20	Stannsoporfin compositions and administration
ZA200709692B (en)	2008-11-26	Antineoplastic compounds and pharmaceutical compositions thereof
EP1805154A4 (fr)	2009-11-25	Compositions pharmaceutiques
GB0522045D0 (en)	2005-12-07	Pharmaceutical compositions
EP1871348A4 (fr)	2012-08-01	Compositions pharmaceutiques a liberation prolongee
SI1888040T1 (sl)	2010-12-31	Farmacevtski sestavki, ki obsegajo imatinib in sredstvo za upočasnitev sproščanja
EP1845944A4 (fr)	2011-07-27	Compositions pharmaceutiques
GB0407351D0 (en)	2004-05-05	Pharmaceutical compositions
EP1865777A4 (fr)	2008-07-16	Compositions de stannsoporfine et administration
GB0400971D0 (en)	2004-02-18	Pharmaceutical compositions
ZA200803566B (en)	2009-10-28	Pharmaceutical compositions